260 related articles for article (PubMed ID: 20054641)
1. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Masri S; Phung S; Wang X; Chen S
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
[TBL] [Abstract][Full Text] [Related]
4. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
6. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
9. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
10. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
11. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Wong C; Wang X; Smith D; Reddy K; Chen S
Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
[TBL] [Abstract][Full Text] [Related]
12. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
13. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
14. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
[TBL] [Abstract][Full Text] [Related]
16. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Gilani RA; Kazi AA; Shah P; Schech AJ; Chumsri S; Sabnis G; Jaiswal AK; Brodie AH
Breast Cancer Res Treat; 2012 Oct; 135(3):681-92. PubMed ID: 22878889
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
[TBL] [Abstract][Full Text] [Related]
18. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Chen HY; Liu ZH
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
[TBL] [Abstract][Full Text] [Related]
20. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
